On 3 January 2021, Covaxin became India's first indigenously produced vaccine against the novel coronavirus to get 'emergency approval in public health interest in clinical trial mode.’ 

The vaccine is jointly made by Bharat Biotech, Indian Council of Medical Research and National Institute of Virology. 

However, its approval raised many questions, especially since phase 3 clinical trials were still ongoing and no efficacy data had been published.

Several media outlets in January 2021 reported on the vaccine’s clinical trial at People’s Hospital Bhopal, one of the several sites where phase 3 trials are taking place. The reports pointed to how poor people were lured without any understanding that they were taking part in a vaccine trail and not a vaccination drive. 

There has been one death and several participants have reported illnesses at this site. 

Why are there fears of ethical breaches in the clinical trail and what does it mean for Covaxin?

Producer and Host: Himmat Shaligram

Priyanka Pulla, freelance science journalist

Editor: Shelly Walia

Music: Big Bang Fuzz

Apple: https://apple.co/2AYdLIl

Saavn: http://bit.ly/2oix78C

Google Podcasts: http://bit.ly/2ntMV7S

Spotify: https://spoti.fi/2IyLAUQ

Deezer: http://bit.ly/2Vrf5Ng

Castbox: http://bit.ly/2VqZ9ur